

2024



NUCLEIC ACID INSIGHTS

EDITORIAL CALENDAR

	JANUARY	FEBRUARY	MARCH	APRIL	MAY	JUNE
Special Editions	Special Launch Issue (see page 2 for details)	Delivery & Formulation			mRNA Processing & Analysis	
Monthly content focus			mRNA: Processing	mRNA: Regulation		mRNA: Engineering and design
			Oligonucleotides: Targeting & delivery	Oligonucleotides: Manufacturing		Oligonucleotides: Analytics & CMC
			pDNA: Analytics & CMC	pDNA: Processing		pDNA: Supply chain
			Formulation & delivery: Regulation	Formulation & delivery: LNPs		Formulation & delivery: Stability
	JULY	AUGUST	SEPTEMBER	OCTOBER	NOVEMBER	DECEMBER
Special Editions			Oligonucleotide Manufacture & Supply Chain			Plasmid DNA
Monthly content focus	mRNA: Preclinical & translational tools	mRNA: Clinical development strategy		mRNA: Processing	mRNA: Analytics & CMC	
	Oligonucleotides: Clinical development strategy	Oligonucleotides: Emerging modalities		Oligonucleotides: Conjugated oligos	Oligonucleotides: Research, preclinical and translational R&D strategy	
	pDNA: Analytics & CMC	pDNA: Processing		pDNA: Next-generation technologies	pDNA: Regulation	
	Formulation & delivery: Guide RNA innovation	Formulation & delivery: Extracellular vesicles		Formulation & delivery: LNPs	Formulation & delivery: RNA/DNA delivery of genome editing platforms	

Contact Nicola McCall on +44 1732 463215 or n.mccall@insights.bio to discuss thought leadership and lead generation opportunities

2024

EDITORIAL CALENDAR

Spotlights summary

JANUARY

FEBRUARY

MARCH

Delivery & Formulation

APRIL

MAY

JUNE

mRNA Processing
& Analysis

JULY

AUGUST

SEPTEMBER

Innovation in
Oligonucleotide
Manufacture
& Supply Chain

OCTOBER

NOVEMBER

DECEMBER

Plasmid DNA

NUCLEIC ACID INSIGHTS SPECIAL LAUNCH EDITION JANUARY 2024

The inaugural edition of ***Nucleic Acid Insights*** features a wide variety of stakeholders from across the nucleic acids space sharing their perspectives on recent progress, current challenges, and future directions in the field.

Confirmed contributors to this special edition include:

John Counsell, Associate Professor, University College London

Floris Engelhardt, CEO, Kano Therapeutics

John Lewis, CEO, Entos Pharmaceuticals

Chris Mason, Professor of Cell and Gene Therapy, Advanced Centre for Biochemical Engineering, University College London

Myriam Mendila, Chief Development Officer, Curevac

Nizar Saad, Assistant Professor, The Ohio State University Medical School; Department of Pediatrics, Nationwide Children's Research Institute

Hartak Singh, Managing Director, Oppenheimer & Co. Inc.

2024

EDITORIAL CALENDAR Spotlight details

Nucleic Acid Insights' Spotlights provide you with fantastic opportunities to:

- Educate your target market** about your company's expertise, capabilities and experience
- Share your latest data** with organisations looking for partners and service providers in your field
- Profile your executives and scientists** as thought-leaders and KOLs
- Generate qualified leads** from across the global sector
- Increase awareness** of your company's role in cell and gene therapy R&D and manufacture.

Each spotlight will comprise:

- Peer-reviewed Reviews and Expert Insight articles** written by leading experts in the field
- Webinars**, featuring industry speakers and sponsors discussing key topics specific to the Spotlight
- Podcast, written and video interviews** with key opinion leaders
- On demand **roundtable discussions**

FEB

Delivery & Formulation

- ▶ Tissue-specific targeting – which approaches are proving to be optimal?
 - ▶ How and where can we move beyond the liver ?
- ▶ Nanoparticles (lipid and polymer)
 - ▶ Overcoming freedom to operate barriers
- ▶ Extracellular vesicles
- ▶ Chemical conjugates
- ▶ Exploring novel techniques for oligonucleotide formulation / encapsulation
- ▶ Optimizing RNA stability
- ▶ Addressing toxicity issues in DNA delivery
- ▶ Advancing non-temperature-dependent formulation

MAY

mRNA Processing & Analysis

- ▶ How to reduce CoGs?
- ▶ Process optimization
 - ▶ How to drive improvements in scalability and consistency?
 - ▶ What are advances in mRNA manufacturing automation and the application of single-use technologies delivering in practice?
 - ▶ How best to address potential downstream purification issues in upstream processing?
 - ▶ Needs and opportunities in downstream processing

SEP

Innovation in Oligonucleotide Manufacture & Supply Chain

- ▶ How to address the growing shortfall in supply of GMP-grade synthesized oligos?
- ▶ What progress in enhancing capabilities while controlling costs in oligo synthesis?
- ▶ How to improve the sustainability of oligo manufacturing?

DEC

Plasmid DNA

- ▶ How to address the ongoing supply bottleneck?
 - ▶ Improving and accelerating plasmid manufacturing processes
- ▶ How great a threat do synthetic approaches really present to pDNA?
- ▶ Improving pDNA processing productivity, quality, consistency, and cost effectiveness
 - ▶ Single-use systems
 - ▶ What are the 'must-do's' to ensure pDNA quality (both for use as a starting material and as a drug product)?